Background-Ischemic
L ethal reperfusion injury accounts for up to 50% of the final size of a myocardial infarct. 1 Ischemic preconditioning is one of the most effective methods to reduce lethal reperfusion injury and has shown consistent cardioprotective effects in animal experiments. 2, 3 However, the inability to predict the exact timing of the onset of ischemia makes its clinical application very difficult. Ischemic postconditioning is repetitive reversible brief ischemia during the early period of reperfusion after the prolonged ischemic insult 4 and appears to share common mechanisms with ischemic preconditioning to reduce lethal reperfusion injury. 3 Animal studies
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have demonstrated that postconditioning has cardioprotective effects that are comparable to those of preconditioning. 4 Contrary to preconditioning, ischemic postconditioning can be directly applicable to primary percutaneous coronary intervention (PCI) because repetitive occlusion of a short duration with an angioplasty balloon can be performed after reopening of the occluded coronary arteries to trigger postconditioning. Several small human trials reported that ischemic postconditioning with primary PCI significantly reduced enzymatic infarct size compared with conventional primary PCI in patients with ST-segment-elevation myocardial infarction (STEMI). [5] [6] [7] However, the results of studies using magnetic resonance imaging to evaluate the effects of postconditioning on infarct size were inconsistent. [8] [9] [10] [11] [12] Moreover, most studies have not reflected current practice patterns such as thrombus aspiration, predilation before stenting, or use of glycoprotein IIb/IIIa inhibitors. Until now, cardioprotective effects of ischemic postconditioning have not been demonstrated in a large-scale trial. Therefore, in the Effects of Postconditioning on Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction (POST) trial, we assessed the hypothesis that postconditioning improves myocardial reperfusion after primary PCI.
Methods
Study Design and Patients
The POST trial was a multicenter, prospective, randomized, openlabel, blinded end-point trial. The authors designed the study, and the institutional review board at each participating center approved the trial protocol. This study was coordinated by the Clinical Trial Center of Samsung Medical Center (Seoul, Korea). Patients were eligible for the trial if they had acute STEMI within 12 hours after symptom onset and primary PCI was planned. Inclusion criteria were as follows: (1) the presence of chest pain for <12 hours after symptom onset, (2) ST-segment elevation >1 mm in ≥2 contiguous leads, (3) Thrombolysis in Myocardial Infarction (TIMI) grade 0 or 1 flow in the infarct-related artery, and (4) target lesion in a native coronary vessel with reference diameter of 2.25 to 4.25 mm. Exclusion criteria were (1) hemodynamic instability or cardiogenic shock, (2) left bundle-branch block on ECG, (3) left main lesion, (4) rescue PCI after thrombolysis or facilitated PCI, (5) noncardiac comorbid conditions with a life expectancy <1 year or that may result in protocol noncompliance (per the site investigator's medical judgment), or (6) female of childbearing potential, unless a recent pregnancy test was negative, who possibly planned to become pregnant any time after enrollment in this study. All patients provided written informed consent.
Randomization and Study Procedures
Patients were randomly assigned to the postconditioning group or the conventional primary PCI group in a 1:1 ratio after diagnostic angiography. Randomization was performed with a Web-based response system and was stratified by the site of enrollment and infarct-related artery (left anterior descending artery versus not left anterior descending artery).
PCI was performed according to standard techniques. Before the index procedure, all patients received 300 mg aspirin and 600 mg clopidogrel as loading doses. Unfractionated heparin was administered intravenously before PCI, and the active clotting time was maintained at >250 seconds throughout the procedure. Thrombus aspiration, predilation before stenting, or use of glycoprotein IIb/IIIa inhibitors was left to the operators' discretion. In the postconditioning group, immediately (within 1 minute) after restoration (TIMI grade ≥2) of coronary flow (without regard to method of restoration), an angioplasty balloon was positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (<6 atm) inflations, with each instance of inflation separated by 1 minute of reflow. 5 The starting pressure was at the discretion of operators, but a small dose of dye was injected during balloon inflation to ensure reocclusion of coronary flow. If coronary flow was not occluded completely, operators were recommended to increase inflation pressure gradually with a subsequent dye test.
After the procedure, creatine kinase-MB was measured at each participating center before PCI and every 8 hours for 48 hours after the index procedure. Thereafter, creatine kinase-MB was measured once daily until normalized. All patients were recommended to receive optimal pharmacological therapy, including statins, β-blockers, or renin-angiotensin system blockade, following the current guidelines. Dual antiplatelet therapy (aspirin 100-200 mg/d plus clopidogrel 75 mg/d) was recommended for at least 12 months.
Study End Points
The primary end point was the rate of complete ST-segment resolution on ECG obtained 30 minutes after the procedure. The sum of ST-segment elevation was measured 20 milliseconds after the end of the QRS complex from leads I, aVL, and V 1 through V 6 for anterior myocardial infarction and leads II, III, aVF, and V 5 and V 6 for nonanterior myocardial infarction. 13 ST-segment resolution was categorized as complete (>70%), partial (30%-70%), or absent (<30%). 13 Secondary end points included residual ST-segment deviation, TIMI flow after PCI, myocardial blush grade, death, reinfarction, severe heart failure, stent thrombosis, target vessel revascularization, and major adverse cardiac events (a composite of death, myocardial infarction, severe heart failure, or stent thrombosis) at 30 days. Residual ST-segment deviation was categorized as <1, 1-3, 4-6, and >6 mm on the basis of a previous study.
14 Evaluation of myocardial blush grade was performed by use of the angiograms made at the end of the index procedures as previously described: 0=absence of contrast opacification in the myocardial infarct zone or persistent staining without washout; 1=minimal contrast opacification; 2=reduced but clearly evident blush in the infarct zone compared with the ipsilateral or contralateral noninvolved epicardial vessel(s); and 3=myocardial contrast filling equal to or greater than that seen in the noninvolved epicardial vessel(s). 15 All deaths were considered cardiac unless a definite noncardiac cause could be established. Myocardial infarction was defined according to the Academic Research Consortium classification. 16 When cardiac enzymes (creatine kinase-MB or troponin-T/troponin-I) were elevated, reinfarction was defined as stable or decreasing values on 2 samples and a 20% increase 3 to 6 hours after the second sample. After cardiac enzymes normalized, myocardial infarction was defined as a cardiac enzyme increase greater than the upper normal limit. Severe heart failure was defined as heart failure with documented arterial partial pressure of oxygen <60 mm Hg or with pulmonary edema documented radiographically or requiring intubation, 100% oxygen, or insertion of a mechanical support device. 17 Stent thrombosis was defined as definite or probable according to the Academic Research Consortium classification. 16 ECG and angiographic data were analyzed at the core laboratory (Samsung Medical Center, Seoul, Korea). The independent clinical event adjudication committee, the members of which were unaware of the study group assignments, assessed all of the clinical end points. An independent data safety monitoring board reviewed the data periodically.
Statistical Analysis
To test the hypothesis that postconditioning adjunctive to primary PCI is superior to conventional primary PCI for improving myocardial reperfusion, we assumed a 50% rate of complete ST-segment resolution with conventional primary PCI on the basis of previous well-conducted studies. 17, 18 We hypothesized that postconditioning would increase the rate of complete ST-segment resolution by 12.5% (relative increase, 25%), leading to a final percentage of 62.5%. On the basis of the estimated improvement in the primary end point, we selected a target sample size of 700 subjects, which would provide by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from 91.7% power at the 0.05 significance level to detect anticipated differences and to offer some protection against the smaller effect size than anticipated.
Originally, we planned to perform all analyses according to the intention-to-treat principle. However, in terms of ST-segment resolution, myocardial blush grades, and TIMI flow grades, data were not available for a few patients. Therefore, we had to perform analyses according to the modified intention-to-treat principle for these end points. All other analyses were performed according to the intention-to-treat principle. Categorical variables were compared by use of the χ 2 test. Continuous variables were compared by use of the Student t test or the Mann-Whitney U test as appropriate. We also performed prespecified subgroups analyses to evaluate the consistency of treatment effects. Predefined subgroups were infarct-related artery (left anterior descending artery versus not left anterior descending artery), time from symptom onset to reperfusion (<3 versus ≥3 hours), thrombus aspiration versus no thrombus aspiration, direct stenting, and use of glycoprotein IIb/IIIa inhibitors. A post hoc analysis was done for age (<65 versus ≥65 y) and sex. A value of P<0.05 in the 2-tailed test was considered significant. All analyses were performed with a Statistical Analysis Software package (SAS version 9.1, SAS Institute, Cary, NC).
Results
Patients and Treatment
Between July 2009 and June 2012, we screened 3916 patients with STEMI undergoing primary PCI at 17 centers (Figure 1 ). Of these, a total of 700 (17.9%) were enrolled and randomly assigned to either the postconditioning group (n=350) or the conventional PCI group (n=350). Baseline clinical and angiographic characteristics were well balanced between the 2 groups (Table 1) .
One patient in the conventional PCI group underwent emergent coronary artery bypass grafting surgery because of failure of guidewire passage. Predilation before stenting was performed in most patients, and thrombus aspiration was performed in about half of the patients. Obtaining reflow in the infarct-related artery was achieved in a similar way in the postconditioning and conventional PCI groups, mostly by predilation ballooning or thrombus aspiration. Among the patients assigned to the postconditioning group, balloon occlusion immediately after reflow was performed for 4 cycles per protocol in 323 patients (92.3%). The ischemic postconditioning procedure was not initiated because of hemodynamic instability immediately after reflow in 3 patients and inability to obtain TIMI grade ≥2 flow in 1 patient. In 23 patients, balloon occlusion for ischemic postconditioning was performed for <4 cycles. The reasons for failure to complete 4 cycles of balloon occlusion were intolerable chest pain (n=6), thrombi formation or aggravation (n=2), ventricular fibrillation (n=1), bradycardia (n=1), and operator decision (n=13). Patients who developed ventricular fibrillation were resuscitated after defibrillation. The ischemic postconditioning procedure was performed before stenting in all except 1 patient from each group.
End Points
Baseline and follow-up ECG data were available for analysis in 341 patients (97.4%) of the postconditioning group and 335 patients (95.7%) of the conventional PCI group (P=0.21). The median time from the last contrast injection to the postprocedural ECG was 31 minutes (interquartile range, 29-38 minutes) in the postconditioning group and 31 minutes (interquartile range, 29-37 minutes) in the conventional PCI group (P=0.77). The primary end point of complete ST-segment resolution occurred in 138 of the 341 patients (40.5%) in the postconditioning group and 139 of the 335 patients (41.5%) in the postconditioning group (absolute difference, −1.0%; 95% confidence interval, −8.4 to 6.4; P=0.79; Figure 2A ). Residual ST-segment deviation was not significantly different between the groups (P=0.99; Figure 2B ). The rates of complete ST-segment resolution were 49.1% in the postconditioning group and 50.9% in the conventional PCI group (P=0.69) at least 4 hours after the procedure. Although the rates of complete ST-segment resolution increased compared with those at 30 minutes after the index procedure, the rates were not significantly different between the 2 groups.
In the per-protocol analysis, the rate of complete ST-segment resolution was 40.6% in the postconditioning group versus 41.6% in the conventional PCI group (absolute difference, −1.0%; 95% confidence interval, −8.5 to 6.6; P=0.80). In the subgroup analyses, a cardioprotective effect of postconditioning for improved ST-segment resolution was not found in any of the subgroups (Figure 3) .
There was no significant difference in the postprocedural myocardial blush grade of 0 or 1 between the 2 groups (17.2% versus 22.4%; P=0.20; 
Discussion
In this prospective, randomized trial, ischemic postconditioning with primary PCI did not improve ST-segment resolution to a greater extent than conventional primary PCI. Moreover, postprocedural myocardial blush grade, TIMI flow grade, and rate of 30-day major adverse cardiac events were not significantly different between the randomized groups. Cardioprotective effects of postconditioning were not found in any of the prespecified subgroups. Despite timely and successful reperfusion with primary PCI, the mortality rate remains high, 19 and a substantial number of patients suffer from subsequent left ventricular dysfunction or heart failure after STEMI. 20 Abrupt reperfusion after prolonged coronary occlusion can induce myocardial and vascular injury, which in turn contributes to increasing infarct size and impairing left ventricular function. 1 Therefore, adjunctive therapy that is effective in preventing lethal reperfusion injury is needed to potentiate the benefits of primary PCI.
Ischemic postconditioning has been reported to reduce infarct size in patients with STEMI undergoing primary PCI in small clinical trials. [5] [6] [7] However, these studies had small sample sizes (mostly <100 patients) and were typically conducted at a single center. Moreover, the data on infarct size measured by cardiac magnetic resonance imaging have been inconsistent among 5 previous studies. Although 2 studies reported that ischemic postconditioning reduced infarct size or increased myocardial salvage, 8, 12 infarct size did not differ significantly between the 2 treatment groups in 1 study. 9 Notably, postconditioning showed harmful effects in 2 other studies. 10, 11 The contradictory findings in previous studies may be attributable to differences in PCI procedures. Studies in which only direct stenting was allowed or was predominantly performed demonstrated the beneficial effects of ischemic postconditioning, 5, 8, 12 whereas studies in which primary PCI was performed according to current standard practice such as predilation or thrombus aspiration failed to demonstrate the beneficial effects of ischemic postconditioning. 9, 10 Concordantly, a recent meta-analysis suggested that the protective effects of ischemic postconditioning are more pronounced among patients in whom direct stenting techniques are used. 21 Therefore, we conducted this trial to evaluate the efficacy and safety of postconditioning in patients undergoing primary PCI with current standard practice. The number of enrolled patients, which outweighed those of previous studies, and the multicenter design made our trial more reliable and conclusive than previous studies.
There is a possibility that our findings may result from study design rather than lack of actual benefit from ischemic postconditioning. First, thrombus aspiration was performed in nearly half of the patients in our study, whereas thrombus aspiration was not performed or was performed in only a minority of patients in previous studies. 5, 8, 12 The cardioprotective effects of postconditioning may be attenuated by thrombus aspiration because thrombus aspiration was reported to improve myocardial reperfusion. 18 Moreover, if reflow is obtained by thrombus aspiration, the initiation of postconditioning may be delayed because an aspiration catheter has to be withdrawn and an angioplasty balloon has to be inserted and positioned at the culprit lesion site. In turn, a delay between reflow and the first reocclusion may abrogate the cardioprotective effect of postconditioning. However, the cardioprotective effect of postconditioning was reported not to be lost when the intervention of postconditioning was delayed to 30 minutes after reperfusion in an animal study. 22 Prespecified subgroup analyses showed that the effect of postconditioning did not differ as a result of thrombus aspiration in our trial. Second, the sequence of postconditioning procedure and stenting may affect the cardioprotective effects of ischemic postconditioning. In this study, we allowed thrombus aspiration and predilation before stenting to reflect the current standard practice pattern of primary PCI, and reflow was achieved mostly by predilation ballooning or thrombus aspiration. As a result, stents were implanted after postconditioning procedures in nearly all of the patients. Therefore, embolization resulting from stenting may dilute the cardioprotective effect of postconditioning. However, direct stenting has been reported to be used in fewer than one-third of patients undergoing primary PCI. 23, 24 Moreover, direct stenting is not feasible in some patients with TIMI grade 0 flow because the distal segment beyond the culprit lesion cannot be evaluated. In our study, no significant benefit of postconditioning was observed in patients undergoing direct stenting. Together, these findings indicate that it is unlikely that ischemic postconditioning is protective in patients undergoing primary PCI with current standard practice.
Although the exact mechanism is not fully elucidated, the cardioprotective effects of ischemic postconditioning demonstrated in animal studies are thought to be mediated by activating the reperfusion injury salvage kinase pathway 3 and inhibiting the opening of the mitochondrial permeability transition pore. 25, 26 Because these mechanisms play important roles in reperfusion injury, an alternative approach such as pharmacological agents to manipulate the reperfusion injury salvage kinase pathway and the mitochondrial permeability transition pore appears promising. 27 By conditioning myocardium pharmacologically, we can avoid repeat balloon occlusion after restoration of coronary reflow, which can potentially aggravate ischemia or cause distal embolization. Large, randomized, clinical trials such as the Cyclosporine and Prognosis in Acute Myocardial Infarction Patients (CIRCUS) trial (NCT01502774) are needed to confirm the efficacy of this new approach.
Our study has several limitations. First, the sample size was inadequate to allow definite conclusions on clinical outcomes. However, our primary end point, complete ST-segment resolution, is well correlated with subsequent mortality and congestive heart failure in patients with STEMI. 28 Moreover, no significant differences were observed between the 2 groups in terms of myocardial blush grade or postprocedural TIMI flow grade, which are also well-established surrogates for clinical outcomes. 18, 29 Our enzyme data were representative among studies on the effects of ischemic postconditioning 7, 10 and support our findings of no significant difference in the complete ST-segment resolution, although creatine kinase-MB was not measured at the core laboratory. Second, this study was not a double-blind study. However, ECG and angiographic findings were analyzed blindly at the core laboratory. Clinical events were assessed by the independent clinical event adjudication committee. Third, postconditioning was not performed per protocol in ≈8% of patients. However, when we performed a per-protocol analysis, the rate of complete ST-segment resolution was also similar in the 2 groups. Fourth, we did not systematically collect angiographic or ECG evidence for reocclusion of coronary flow during balloon inflation. However, balloon occlusion for ischemic postconditioning was performed before stenting or acquiring large lumen in most patients, minimizing the possibility that reocclusion might be incomplete. Finally, we excluded patients with hemodynamic instability or left main lesion who might have had lethal reperfusion injury and may have received potential benefits from ischemic postconditioning. However, it is not feasible to perform repeat occlusion after the restoration of coronary flow in such situations because of complete blockage of coronary flow in the left main stem or the vulnerability of patients. CI indicates confidence interval; and PCI percutaneous coronary intervention. Clinical follow-up data at 1 month were available in all patients. The percentages shown are calculated by the intention-to-treat analysis. P values were calculated with the use of the χ 2 test unless otherwise noted. *Relative risk is for the postconditioning group compared with the conventional PCI group. †Major adverse cardiac event was a composite of death, myocardial infarction, severe heart failure, and stent thrombosis. 
Conclusions
This multicenter, prospective, randomized trial demonstrated that ischemic postconditioning did not improve myocardial reperfusion in patients with STEMI undergoing primary PCI. Further studies are warranted to investigate other strategies such as pharmacological conditioning to prevent lethal reperfusion injury.
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